Aclaris therapeutics announces sale of olumiant® royalties and milestones to omers life sciences for up to $31.5 million

- non-dilutive transaction strengthens balance sheet to support strategic priorities - - $26.5 million upfront plus up to $5.0 million milestone - wayne, pa., july 16, 2024 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of aclaris' future royalty payments and certain milestones from eli lilly and company (lilly) on net sales of olumiant® (baricitinib) for the treatment of alopecia areata to omers, one of canada's largest defined benefit pension plans.
ACRS Ratings Summary
ACRS Quant Ranking